BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rogler G. Efficacy of JAK inhibitors in Crohn's Disease. J Crohns Colitis 2020;14:S746-54. [PMID: 31781755 DOI: 10.1093/ecco-jcc/jjz186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu L, Shen J, Zheng Q. Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's disease. Int J Colorectal Dis 2020;35:2019-26. [PMID: 32577870 DOI: 10.1007/s00384-020-03679-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Cheng WX, Ren Y, Lu MM, Xu LL, Gao JG, Chen D, Kalyani FS, Lv ZY, Chen CX, Ji F, Lin HN, Jin X. Palmitoylation in Crohn’s disease: Current status and future directions. World J Gastroenterol 2021; 27(48): 8201-8215 [DOI: 10.3748/wjg.v27.i48.8201] [Reference Citation Analysis]
3 Gilardi D, Gabbiadini R, Allocca M, Correale C, Fiorino G, Furfaro F, Zilli A, Peyrin-biroulet L, Danese S. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Review of Gastroenterology & Hepatology 2020;14:797-806. [DOI: 10.1080/17474124.2020.1785868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mohanakrishnan R, Beier S, Deodhar A. Tofacitinib for the treatment of active ankylosing spondylitis in adults. Expert Rev Clin Immunol 2022. [PMID: 35152808 DOI: 10.1080/1744666X.2022.2038134] [Reference Citation Analysis]
5 Danese S, Peyrin-Biroulet L. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. Inflamm Bowel Dis 2021:izab135. [PMID: 34089259 DOI: 10.1093/ibd/izab135] [Reference Citation Analysis]
6 Lei H, Crawford MS, McCole DF. JAK-STAT Pathway Regulation of Intestinal Permeability: Pathogenic Roles and Therapeutic Opportunities in Inflammatory Bowel Disease. Pharmaceuticals (Basel) 2021;14:840. [PMID: 34577540 DOI: 10.3390/ph14090840] [Reference Citation Analysis]
7 Lee SD, Singla A, Harper J, Barahimi M, Jacobs J, Kamp KJ, Clark-Snustad KD. Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn's Disease. Dig Dis Sci 2022. [PMID: 35288831 DOI: 10.1007/s10620-022-07444-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel) 2021;11:2035. [PMID: 34443866 DOI: 10.3390/nano11082035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Parigi TL, Solitano V, Peyrin-Biroulet L, Danese S. Do JAK inhibitors have a realistic future in treating Crohn's disease? Expert Rev Clin Immunol 2021;:1-3. [PMID: 34971341 DOI: 10.1080/1744666X.2022.2020101] [Reference Citation Analysis]
10 Karki R, Kanneganti TD. The 'cytokine storm': molecular mechanisms and therapeutic prospects. Trends Immunol 2021;42:681-705. [PMID: 34217595 DOI: 10.1016/j.it.2021.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 Pathway in Crohn's Disease. Front Immunol 2021;12:622934. [PMID: 33859636 DOI: 10.3389/fimmu.2021.622934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Devaprasad A, Radstake TRDJ, Pandit A. Integration of Immunome With Disease-Gene Network Reveals Common Cellular Mechanisms Between IMIDs and Drug Repurposing Strategies. Front Immunol 2021;12:669400. [PMID: 34108969 DOI: 10.3389/fimmu.2021.669400] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 La Manna S, De Benedictis I, Marasco D. Proteomimetics of Natural Regulators of JAK-STAT Pathway: Novel Therapeutic Perspectives. Front Mol Biosci 2021;8:792546. [PMID: 35047557 DOI: 10.3389/fmolb.2021.792546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wang L, Song B, Hu Y, Chen J, Zhang S, Chen D, Wang J. Puerarin Ameliorates 5-Fluorouracil-Induced Intestinal Mucositis in Mice by Inhibiting JAKs. J Pharmacol Exp Ther 2021;379:147-55. [PMID: 34400527 DOI: 10.1124/jpet.121.000677] [Reference Citation Analysis]
15 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]
16 Akkoc N, Khan MA. JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold? Curr Rheumatol Rep 2021;23:34. [PMID: 33909185 DOI: 10.1007/s11926-021-01001-1] [Reference Citation Analysis]
17 Nielsen OH, Boye TL, Chakravarti D, Gubatan J. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends Pharmacol Sci 2022:S0165-6147(22)00032-3. [PMID: 35277286 DOI: 10.1016/j.tips.2022.02.008] [Reference Citation Analysis]
18 Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Mod Rheumatol 2021;:1-11. [PMID: 33740386 DOI: 10.1080/14397595.2021.1902617] [Reference Citation Analysis]
19 Nwaogu A, Bond A, Smith PJ. Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis - NICE guidance. Frontline Gastroenterol 2021;12:133-6. [PMID: 33613945 DOI: 10.1136/flgastro-2020-101502] [Cited by in F6Publishing: 1] [Reference Citation Analysis]